ArticlePloS one2025
The relationship between sarcopenic obesity and cognitive functionality among inpatients with stable schizophrenia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Visceral Adiposity Is Associated with Elevated Interleukin-1 Receptor Antagonist Levels and Anxiety Symptoms in Schizophrenia.International journal of molecular sciences · 2026Article
- Inflammation and sarcopenia exhibit distinct associations with psychopathology and executive function in schizophrenia.Journal of the Chinese Medical Association : JCMA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesPatients with schizophrenia face an elevated risk of sarcopenic obesity (SO) due to antipsychotic-induced metabolic dysfunction, physical inactivity, and nutritional deficiencies. Although recent studies suggest an association between SO and cognitive decline, its specific impact on cognitive function in schizophrenia remains to be fully elucidated. This study aimed to evaluate the diagnostic concordance between the European Society for Clinical Nutrition and Metabolism/European Association for the Study of Obesity (SOESPEN) criteria and its modified version (SOESPEN-M), and to examine their respective associations with cognitive function in inpatients with stable schizophrenia.
methodsIn this cross-sectional analysis, 228 adults with stable schizophrenia were recruited. SO was diagnosed using two definitions: SOESPEN (excess adiposity, low muscle mass-to-weight ratio, and reduced handgrip strength) and SOESPEN-M (BMI-adjusted muscle mass threshold). Cognitive function was assessed using the Montreal Cognitive Assessment-Chinese version (MoCA-C). Multivariate linear regression models were employed to evaluate associations between SO and MoCA-C scores, adjusting for relevant demographic, clinical, and comorbidity-related variables.
resultsSO prevalence was 17.1% under both diagnostic criteria, with moderate inter-criteria agreement (κ = 0.660). Sex-stratified analyses revealed divergent diagnostic trends: in males, SO prevalence increased from 15.9% (SOESPEN) to 22.5% (SOESPEN-M; κ = 0.698); in females, prevalence decreased from 18.9% to 8.9% (κ = 0.590). Across both criteria, SO groups demonstrated significantly lower MoCA-C scores (males: 16 vs 20, p = 0.045 for SOESPEN; 13 vs 21, p < 0.001 for SOESPEN-M; females: 11 vs 17, p = 0.009 for SOESPEN; 10.5 vs 17, p = 0.036 for SOESPEN-M). Multivariate analysis confirmed that SOESPEN-M-defined SO was independently associated with lower MoCA-C scores in males (β = -2.71, 95% CI: -5.08 to -0.33, p = 0.027).
conclusionOur results demonstrate that SO defined by SOESPEN-M criteria is significantly associated with cognitive impairment in male inpatients with stable schizophrenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.